A Prospective, Randomized Multicenter Trial of Cilostozal vs Ticlopidine in Patients Undergoing Stent Implantation - RACTS
The goal of the trial was to compare the effect of post PCI treatment using Cilostazol vs ticlopidine in addition to aspirin as the antiplatelet regimen.
Patients Enrolled: 397
Mean Follow Up: 9 months
This is a Chinese prospective multicenter randomized study involving 397 patients. Endpoints were restenosis rate in 6 months and TVR in 9 months
Cilostazol was given at 100mg twice a day and ticlopidine was given at 250mg twice a day.
There is no difference in restenosis rate or MLD at followup. There is a difference in TVR at 9 months 25.3% vs 34.5%, p=0.02.
Compared with ticlopidine, cilostazol appeared to have no clear effect in reducing restenosis, but it seems to have global effect on the vessel. These findings warrant further exploration. There is evidience that Cilostazol may be effective in reducing restenosis as well in animal and small human studies, however, a larger PCI trial did not show that it is effective.
Ge J, Han Y, Jiang H, et al. RACTS: a prospective randomized antiplatelet trial of cilostazol versus ticlopidine in patients undergoing coronary stenting: long-term clinical and angiographic outcome. J Cardiovasc Pharmacol. 2005 Aug;46(2):162-6.
Presented at Late-breaking Clinical Trials session at TCT 2003 Conference, Washington, DC.
Keywords: Platelet Aggregation Inhibitors, Coronary Disease, Neuroprotective Agents, Ticlopidine, Fibrinolytic Agents, Tetrazoles, Vasodilator Agents, Bronchodilator Agents, Phosphodiesterase 3 Inhibitors
< Back to Listings